MKGAF (MKGAF) Stock Price & Analysis
MKGAF (MKGAF) rose 7.06% to USD 159.71 as of June 10, 2026 at 00:43 UTC, according to Nexqual real-time market data.
MKGAF last closed at USD 149.19; the session ranged USD 159.71–159.71 on volume of 42 shares. Market capitalization is $69.44B, with a 52-week range of USD 116.68–166.26 (PNK). Source: Nexqual, June 10, 2026 at 00:43 UTC.
Key Statistics (as of June 10, 2026 at 00:43 UTC)
| Price | USD 159.71 |
|---|---|
| Change | ▲ 7.06% (up) |
| Previous Close | USD 149.19 |
| Open | USD 159.71 |
| Day Range | USD 159.71 – 159.71 |
| 52-Week Range | USD 116.68 – 166.26 |
| Volume | 42 shares |
| Market Cap | $69.44B |
| Exchange | PNK |
Technical Analysis (MKGAF)
Nexqual's technical model rates MKGAF "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 00:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.49 (neutral) |
| vs SMA50 | Above (USD 139.08) |
| MACD | 6.25 (positive) |
Analyst Ratings (MKGAF)
Wall Street analysts rate MKGAF "None", per Nexqual as of June 10, 2026 at 00:43 UTC.
| Consensus Rating | None |
|---|
Earnings (MKGAF)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $5.25B |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financials & Fundamentals (MKGAF)
| Total Revenue | $20.96B |
|---|---|
| Revenue Growth (YoY) | -2.80% |
| Gross Margin | +58.93% |
| Operating Margin | +18.22% |
| Profit Margin | +12.08% |
| ROE | +8.53% |
| Debt / Equity | 40.37 |
| Current Ratio | 1.52 |
| Total Cash | $3.77B |
| Total Debt | $12.04B |
| Free Cash Flow | $3.08B |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financial Health Score (MKGAF)
Nexqual rates MKGAF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:43 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 18% |
| Balance Sheet | Solid — $3.77B cash vs $12.0B debt |
| Cash Flow | Solid — FCF $3.08B, 15% margin |
| Efficiency | Mixed — ROE 9%, ROA 4.7% |
Ownership (MKGAF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +58.38% |
| Shares Outstanding | 129.24M |
| Float | 128.95M |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Leadership (MKGAF)
MKGAF is led by Kai Beckmann (age 60), CEO & Chair of Management Board, per Nexqual as of June 10, 2026 at 00:43 UTC.
| CEO & Chair of Management Board | Kai Beckmann (age 60) |
|---|---|
| CFO & Member of Executive Board | Helene von Roeder (age 55) |
| Member of Management Board & CEO of Electronics Business Sector | Benjamin Hein |
Major Backers & Investors (MKGAF)
Notable institutional backers of MKGAF include First Eagle Funds-First Eagle Global Fund, MFS Series Trust XVII-MFS International Equity Fund, Bridge Builder Trust-Bridge Builder International Equity Fund, according to Nexqual as of June 10, 2026 at 00:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Funds-First Eagle Global Fund | 6.29% |
| MFS Series Trust XVII-MFS International Equity Fund | 3.84% |
| Bridge Builder Trust-Bridge Builder International Equity Fund | 1.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.41% |
| BlackRock | 0.71% |
| BNY Mellon | 0.47% |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MKKGY | Merck KGaA | USD 32 | ▲ 2.11% |
| CMXHF | CSL Ltd. | USD 66 | ▼ 6.44% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| LZAGF | Lonza Group AG | USD 615.21 | ▼ 2.89% |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22.85 | ▼ 0.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:43 UTC. This page is informational and not investment advice.